Ask AI

Navigating HER2-Negative MBC: An Oncology Nurse Roadmap to Maximize Efficacy and Enhance Tolerability With Antibody–Drug Conjugates

Slideset

Released: September 02, 2026

See Activity Collection

Downloadable slides on the evolving ADC landscape in the management of patients with HER2-negative metastatic breast cancer, current role of TROP2-directed ADCs, efficacy and safety of TROP2-directed ADCs in advanced breast cancer, ways to optimize adverse event recognition, early intervention and quality-of-life preservation for patients receiving TROP2-directed ADCs, key ongoing trials of TROP2-directed ADCs in breast cancer, role of nurses in providing optimal care for patients receiving ADCs, and multidisciplinary team coordination and shared decision-making to improve patient care.

ADCs for HER2 Negative MBC

Activity Information

Released: September 02, 2026